» Articles » PMID: 19551542

In Vitro Study of Matrix Metalloproteinase/tissue Inhibitor of Metalloproteinase Production by Mesenchymal Stromal Cells in Response to Inflammatory Cytokines: the Role of Their Migration in Injured Tissues

Overview
Journal Cytotherapy
Publisher Elsevier
Date 2009 Jun 25
PMID 19551542
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Background Aims: The transmigratory capacity of bone marrow (BM) mesenchymal stromal cells (MSC) through the endothelial cell barrier into various tissues and their differentiation potential makes them ideal candidates for cell therapy. Nevertheless, the mechanisms and agents promoting their migration are not fully understood. We evaluated the effects of several inflammatory cytokines on the migration of BM MSC and matrix metalloproteinase (MMP)/tissue inhibitor of metalloproteinase (TIMP) production.

Methods: The migratory potential of BM MSC was evaluated using a Boyden chamber coated with Matrigel in the presence and absence of stromal cell-derived (SDF)-1alpha, platelet-derived growth factor (PDGF)bb, insulin-like growth factor (IGF)-I and interleukin (IL)-6. The ability of inflammatory cytokines to induce MSC migration was tested in presence of their respective Ab or blocking peptide. We used immunofluorescence to check the expression of cytokine receptors, and MMP/TIMP production was analyzed at the protein (human cytokine array, enzyme-linked immunosorbent assay (ELISA), gelatine zymography and Western blot) and mRNA quantitative real-time polymerase chain reaction (qRT-PCR) levels.

Results: We have demonstrated that inflammatory cytokines promote the migratory capacity of BM MSC according to the expression of their respective receptors. Higher migration through Matrigel was observed in response to IL-6 and PDGFbb. qRT-PCR and cytokine array revealed that migration was the result of the variable level of MMP/TIMP in response to inflammatory stimuli.

Conclusions: Our observations suggest that chemokines and cytokines involved in the regulation of the immunity or inflammatory process promote the migration of MSC into BM or damaged tissues. One of the mechanisms used by MSC to promote their migration though the extracellular matrix is modulation of the production of MMP-1, MMP-2, MMP-13, TIMP-1 and TIMP-2.

Citing Articles

Pharmacokinetic characteristics of mesenchymal stem cells in translational challenges.

Shan Y, Zhang M, Tao E, Wang J, Wei N, Lu Y Signal Transduct Target Ther. 2024; 9(1):242.

PMID: 39271680 PMC: 11399464. DOI: 10.1038/s41392-024-01936-8.


MSC-Based Cell Therapy in Neurological Diseases: A Concise Review of the Literature in Pre-Clinical and Clinical Research.

Zhang X, Kuang Q, Xu J, Lin Q, Chi H, Yu D Biomolecules. 2024; 14(5).

PMID: 38785945 PMC: 11117494. DOI: 10.3390/biom14050538.


Superior migration ability of umbilical cord-derived mesenchymal stromal cells (MSCs) toward activated lymphocytes in comparison with those of bone marrow and adipose-derived MSCs.

Hori A, Takahashi A, Miharu Y, Yamaguchi S, Sugita M, Mukai T Front Cell Dev Biol. 2024; 12:1329218.

PMID: 38529405 PMC: 10961348. DOI: 10.3389/fcell.2024.1329218.


Immunomodulatory amnion-derived mesenchymal stromal cells preserve muscle function in a mouse model of Duchenne muscular dystrophy.

Nitahara-Kasahara Y, Nakayama S, Kimura K, Yamaguchi S, Kakiuchi Y, Nito C Stem Cell Res Ther. 2023; 14(1):108.

PMID: 37106393 PMC: 10142496. DOI: 10.1186/s13287-023-03337-0.


Associations between IL-1α, IL-1β, TNFα, and IL-6 variations, and susceptibility to transposition of the great arteries.

Atasoy Karakas L, Tugrul D, Sahin Uysal N, Esin S, Tokel N, Terzi Y BMC Cardiovasc Disord. 2022; 22(1):229.

PMID: 35590253 PMC: 9118748. DOI: 10.1186/s12872-022-02670-1.